The impact of Dapagliflozin on epicardial fat volume

The impact of Dapagliflozin on epicardial fat volume - Effects of Dapagliflozin on Body Composition

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035660

Enrollment

Registered

2019-01-24

Start date

2016-06-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Dapagliflozin 5mg/day optimal medical therapy except SGLT-2 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 DM HbA1c>6.5% no history of SGLT2 inhibitor-treatment patients with on-going diet and exercise therapies history of coronary artery disease

Exclusion criteria

Exclusion criteria: age > 75 years insulin therapy atrial fibrillation renal insufficiency (estimated glomerular filtration rate < 45 mL/min/1.73 m2) chronic inflammatory disease coronary artery bypass graft surgery.

Design outcomes

Primary

Measure	Time frame
Epicardial fat volume	—

Countries

Japan

Contacts

Public ContactTakao Sato

Tachikawa general hospital Cardiology

kirotaro19731013@yahoo.co.jp0258-33-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026